Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC).
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2016 Status changed from recruiting to completed, according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 27 Jul 2011 New trial record